A study led by investigators from the Carlos Simon Foundation has been published in Nature Communications, reporting the results of a phase 1/2 clinical trial evaluating a regenerative cell-based therapy in women with moderate to severe Asherman syndrome who did not respond to previous surgical treatment.
Asherman syndrome is a uterine condition characterized by intrauterine adhesions that damage the endometrium and are associated with infertility and recurrent pregnancy loss. In this context, the study assessed the safety and early clinical effects of an autologous cell therapy derived from patients’ own bone marrow and administered directly into the uterus.
The results showed significant improvements in endometrial structure and function, assessed through ultrasound imaging, hysteroscopy, and transcriptomic analyses. The therapy was well tolerated, with no treatment-related serious adverse events reported during follow-up, which included pregnancy and delivery.
Because Asherman syndrome involves damage and loss of functional endometrial tissue, this therapeutic strategy aims to support endometrial regeneration and the recovery of a uterine environment compatible with embryo implantation.
The study was coordinated by researchers from the Carlos Simon Foundation in collaboration with national and international research institutions and hospitals.
Article reference:
Santamaria X, Pardo-Figuerez M, Gonzalez-Fernandez J, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman syndrome: a phase 1/2 trial. Nature Communications (2025). https://doi.org/10.1038/s41467-025-67850-x